文献速递腹部技术与安全CT

动脉受累与可切除性评分系统预测新辅助放化疗后胰腺导管腺癌R0切除

Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
PubMed 文献 · Eur Radiol · 2021-10-19

本研究回顾性纳入112例接受新辅助放化疗的胰腺导管腺癌患者,基于治疗前后动态增强CT建立动脉受累5分制与可切除性4分制的复合AR评分。

要点

  • 治疗前后CT动脉受累与可切除性复合评分可用于预测R0切除。
  • AR总分>9提示总生存与无病生存更差,可作为预后分层参考。
  • 评分需结合新辅助放化疗前后两次增强CT动态评估。

核心结论

  • 整合新辅助放化疗前后动脉受累程度与可切除性状态的复合评分与R0切除相关,并可鉴别R0与R1切除。
  • AR总分>9可预测患者总生存与无病生存更差。

研究设计与样本

  • 回顾性研究,纳入112例接受新辅助放化疗的胰腺导管腺癌患者。
  • 治疗前后均行动态增强CT,采用动脉受累5分制与可切除性4分制评分并计算AR总分(ARtotal)。
  • 分析ARtotal与R0切除、总生存及无病生存的关系。

诊断标准与关键数值

  • 动脉受累5分制:1=无受累,2=模糊,3=接触,4=包绕,5=变形。
  • 可切除性4分制:1=可切除,2=静脉受累的临界可切除,3=动脉受累的临界可切除,4=局部晚期。

临床应用与阅片要点

  • 阅片时按5分制评估动脉受累、按4分制评估可切除性,并分别记录治疗前后评分以计算AR总分。
  • AR总分可作为预测R0切除可能及生存预后的参考指标,辅助多学科决策。

局限性

  • 回顾性研究设计。
  • 单中心样本量有限(112例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT).

METHODS: This retrospective study included 112 patients with PDAC who underwent dynamic contrast-enhanced CT before and after neoadjuvant CRT. A 5-point score was used to determine arterial involvement (A score; 1 = no involvement, 2 = haziness, 3 = abutment, 4 = encasement, 5 = deformity) and 4-point score evaluating resectability status (R score; 1 = resectable, 2 = borderline resectable [BR] with venous involvement, 3 = BR with arterial involvement, 4 = locally advanced [LA]). A score before and after CRT were summed with R score before and after CRT to compute the AR score (ARtotal). The associations between ARtotal, R0 resection, overall survival (OS), and disease-free survival (DFS) were assessed.

RESULTS: The ARtotal was associated with R0 resection (p < .001) and showed area under the ROC curve of 0.79 for differentiating R0 and R1 resections. Median OS was significantly lower for patients with ARtotal > 9 (median: 35.2 months) compared to patients with ARtotal ≤ 9 (median: not estimable) (p < .001). Similar results were observed for DFS (median, 16.8 months in > 9 vs median, not estimable in ≤ 9; p < .001).

CONCLUSIONS: A composite score which incorporates degree of arterial involvement and resectability status before and after neoadjuvant CRT is associated with R0 resection and discriminates between R0 and R1 resections in PDAC.

KEY POINTS: • A scoring system incorporating arterial involvement and resectability status was associated with R0 resection. • ARtotal > 9 could predict patients' overall and disease-free survival.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Noda Y, Pisuchpen N, Mercaldo ND, et al. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2021. PMID: 34665317. doi:10.1007/s00330-021-08304-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。